IRADIMED CORP — Director's Dealing 2021

Dec 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IRADIMED CORP (IRMD)
CIK: 0001325618
Period of Report: 2021-12-07

Reporting Person: Scott Christopher K. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-07	Common Stock	M	1575	—	Acquired	31960	Direct
2021-12-07	Common Stock	F	620	$48.27	Disposed	31340	Direct
2021-12-07	Common Stock	M	2732	—	Acquired	34072	Direct
2021-12-07	Common Stock	F	1076	$48.27	Disposed	32996	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-07	Restricted Stock Units	$	A	4143	Acquired		Common Stock (4143)	Direct
2021-12-07	Performance-Based Restricted Stock Units	$	A	4143	Acquired		Common Stock (4143)	Direct
2021-12-07	Restricted Stock Units	$	M	1575	Disposed		Common Stock (1575)	Direct
2021-12-07	Restricted Stock Units	$	M	2732	Disposed		Common Stock (2731)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F3: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in full on the third anniversary of the grant date, December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F4: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of a specified relative ranking of total stockholder return over a three-year period from December 8, 2021 through December 7, 2024.

F5: If the relative measure at December 7, 2024 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100% and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting will be double the nominal granted shares.

F6: Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested.

F7: On December 7, 2019, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F8: On December 7, 2020, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.